Fourteen percent of the world's people -- more than 800 million -- now have diabetes, a doubling of the global rate for the ...

Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type ...

The study, backed by the WHO, was released to mark World Diabetes Day on Thursday. It conducts a comparison between the ...

Nearly 99% of people with prediabetes and obesity or overweight who took weekly tirzepatide injections remained diabetes-free ...

The detailed results were published in The New England Journal of Medicine and were presented at ObesityWeek 2024.

Tirzepatide shows promise in reducing weight and preventing diabetes progression in people with obesity and prediabetes, with ...

Shocking statistics reveal the rapid rise of diabetes worldwide. Uncover the challenges facing millions and the urgent need ...

The following is a summary of "Adherence and persistence among people with type 2 diabetes newly initiating oral semaglutide ...

Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.

A new study reveals that over 800 million adults globally have diabetes, with more than half of those over 30 not receiving ...

LAHORE: Like other parts of the globe, ‘The World Diabetes Day-2024’ was marked here on Thursday with a resolve to continue ...

The serious health condition affected around 14 percent of all adults worldwide in 2022, compared to seven percent in 1990, ...